American Board of Surgery Qualifying Exam (ABS QE) Practice Test 2026 - Free Surgery Exam Practice Questions and Study Guide

BRCA2 mutations are known to have a significant association with the development of ovarian cancer. Specifically, women with BRCA2 mutations have an approximate lifetime risk of developing ovarian cancer that ranges between 10% to 20%. While estimates can vary in different studies, the general consensus aligns with a figure closer to that 10% mark.

This percentage reflects the penetrance of the BRCA2 mutation with respect to ovarian cancer, which is notably lower than that of BRCA1 mutations, where the risk tends to be higher. In clinical practice, counseling regarding genetic risks typically includes this information, helping to inform decisions about surveillance and potential prophylactic measures.

Since 5% is below the established risk and 30% and 60% exceed the generally accepted statistics for BRCA2, the 10% figure is recognized as accurate based on current genetic epidemiological data.